Your browser is no longer supported. Please, upgrade your browser.
Settings
MYGN [NASD]
Myriad Genetics, Inc.
Index- P/E- EPS (ttm)-1.56 Insider Own2.60% Shs Outstand77.20M Perf Week6.79%
Market Cap2.57B Forward P/E128.26 EPS next Y0.27 Insider Trans-28.16% Shs Float76.80M Perf Month-2.69%
Income-118.00M PEG- EPS next Q-0.04 Inst Own99.70% Short Float6.89% Perf Quarter13.72%
Sales662.30M P/S3.88 EPS this Y63.40% Inst Trans2.60% Short Ratio9.06 Perf Half Y16.09%
Book/sh11.69 P/B2.91 EPS next Y1225.00% ROA-7.00% Target Price30.44 Perf Year170.19%
Cash/sh2.18 P/C15.61 EPS next 5Y-8.20% ROE-10.90% 52W Range11.76 - 36.95 Perf YTD71.88%
Dividend- P/FCF- EPS past 5Y-21.20% ROI-6.10% 52W High-7.26% Beta1.59
Dividend %- Quick Ratio1.90 Sales past 5Y-16.50% Gross Margin70.50% 52W Low191.41% ATR1.46
Employees2700 Current Ratio2.00 Sales Q/Q103.20% Oper. Margin-23.40% RSI (14)52.60 Volatility5.49% 4.14%
OptionableYes Debt/Eq0.12 EPS Q/Q91.80% Profit Margin-14.70% Rel Volume0.31 Prev Close33.99
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume583.71K Price34.27
Recom3.20 SMA20-0.34% SMA502.67% SMA20018.17% Volume58,303 Change0.82%
Jun-15-21Initiated Raymond James Mkt Perform
Jun-03-21Initiated Goldman Sell $25
Sep-26-19Downgrade BofA/Merrill Neutral → Underperform $30 → $28
Aug-14-19Downgrade Piper Jaffray Overweight → Neutral $45 → $40
Aug-02-19Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19Upgrade Barclays Underweight → Equal Weight $18 → $40
Jul-29-19Downgrade Needham Strong Buy → Hold
Jul-09-19Downgrade Cowen Outperform → Market Perform
Mar-12-19Reiterated Needham Strong Buy $37 → $41
Jan-03-19Initiated Needham Strong Buy $36
Nov-30-18Upgrade Goldman Sell → Neutral
Oct-10-18Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18Initiated Goldman Sell $32
Jan-22-18Reiterated Barclays Equal Weight $30 → $35
Jan-05-18Initiated BTIG Research Buy $41
Oct-02-17Resumed Leerink Partners Mkt Perform $31
Aug-09-17Reiterated Barclays Equal Weight $28 → $26
Feb-08-17Upgrade Ladenburg Thalmann Sell → Neutral
Sep-13-21 04:05PM  
Sep-08-21 04:05PM  
08:36AM  
Sep-07-21 09:15AM  
Aug-24-21 11:44AM  
Aug-04-21 08:41AM  
06:51AM  
Aug-03-21 10:01PM  
08:35AM  
07:05AM  
Aug-02-21 07:05AM  
Jul-28-21 04:05PM  
12:57PM  
07:05AM  
Jul-21-21 04:05PM  
Jul-02-21 07:14AM  
Jul-01-21 04:05PM  
Jun-16-21 04:05PM  
Jun-04-21 07:05AM  
Jun-02-21 11:30AM  
10:19AM  
Jun-01-21 07:05AM  
May-31-21 07:22AM  
May-27-21 11:01AM  
09:00AM  
May-24-21 07:05AM  
May-20-21 07:05AM  
May-19-21 05:55PM  
May-05-21 04:05PM  
09:16AM  
May-04-21 08:07AM  
May-03-21 06:35PM  
04:05PM  
07:05AM  
07:00AM  
Apr-28-21 07:05AM  
Apr-27-21 04:05PM  
07:05AM  
Apr-14-21 10:38AM  
Apr-09-21 09:00AM  
Mar-31-21 08:00AM  
Mar-29-21 09:50AM  
07:05AM  
Mar-25-21 11:30AM  
Mar-24-21 06:05PM  
Mar-23-21 09:00PM  
Mar-05-21 10:03AM  
Mar-02-21 07:05AM  
Feb-23-21 08:30PM  
05:10PM  
04:05PM  
02:30PM  
Feb-22-21 10:14AM  
Feb-18-21 04:12PM  
Feb-16-21 04:05PM  
Feb-12-21 07:05AM  
Feb-11-21 04:05PM  
Feb-10-21 11:11AM  
Feb-08-21 07:05AM  
Feb-02-21 07:05AM  
Jan-28-21 12:32PM  
Jan-19-21 07:05AM  
Jan-18-21 08:45AM  
Jan-12-21 08:40AM  
Jan-11-21 02:05PM  
Jan-08-21 07:05AM  
Jan-06-21 10:20AM  
Jan-05-21 04:05PM  
Jan-04-21 07:05AM  
Dec-11-20 07:05AM  
Dec-09-20 11:30AM  
Nov-30-20 11:00AM  
Nov-17-20 07:05AM  
Nov-16-20 07:05AM  
Nov-15-20 08:00PM  
Nov-11-20 07:05AM  
Nov-10-20 08:25AM  
Nov-09-20 09:30PM  
03:15PM  
09:45AM  
08:00AM  
Nov-04-20 07:05AM  
Oct-26-20 12:31PM  
Oct-16-20 09:05AM  
Oct-15-20 07:05AM  
Oct-05-20 12:11PM  
Sep-16-20 10:58AM  
Sep-12-20 11:30AM  
Sep-10-20 07:05AM  
Sep-03-20 06:21PM  
Aug-24-20 11:04AM  
Aug-21-20 07:05AM  
Aug-14-20 04:05PM  
10:46AM  
06:36AM  
12:30AM  
Aug-13-20 06:15PM  
04:19PM  
04:08PM  
04:07PM  
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hart Jayne B.Chief People OfficerSep 17Option Exercise26.4977,0002,039,730153,287Sep 21 06:18 PM
Hart Jayne B.Chief People OfficerSep 17Sale33.7267,4462,274,27988,807Sep 21 06:18 PM
Lambert NicoleSee RemarksAug 27Sale34.5094532,602127,051Aug 30 04:11 PM
LANCHBURY JERRY SChief Scientific OfficerAug 24Option Exercise27.0730,000812,100262,550Aug 25 08:32 PM
LANCHBURY JERRY SChief Scientific OfficerAug 24Sale35.5730,0001,067,100232,550Aug 25 08:32 PM
LANCHBURY JERRY SChief Scientific OfficerAug 23Option Exercise27.0750,0001,353,500272,550Aug 25 08:32 PM
LANCHBURY JERRY SChief Scientific OfficerAug 23Sale35.1750,0001,758,500232,550Aug 25 08:32 PM
Phanstiel S. LouiseDirectorAug 05Option Exercise23.3460,0001,400,400109,527Aug 06 05:43 PM
LANCHBURY JERRY SChief Scientific OfficerAug 05Option Exercise27.0728,225764,051260,775Aug 06 05:47 PM
Phanstiel S. LouiseDirectorAug 05Sale35.0447,8811,677,74161,646Aug 06 05:43 PM
LANCHBURY JERRY SChief Scientific OfficerAug 05Sale35.5728,2251,004,008232,550Aug 06 05:47 PM
LANCHBURY JERRY SChief Scientific OfficerAug 04Option Exercise27.0750,0001,353,500270,775Aug 05 05:18 PM
LANCHBURY JERRY SChief Scientific OfficerAug 04Sale35.3250,0001,766,027232,550Aug 05 05:18 PM
LANGER DENNISDirectorAug 03Option Exercise25.3930,000761,700119,527Aug 05 05:11 PM
LANCHBURY JERRY SChief Scientific OfficerAug 03Option Exercise24.9050,0001,245,210260,380Aug 05 05:18 PM
Riggsbee Richard BryanChief Financial OfficerAug 03Sale35.1414,983526,476324,942Aug 05 05:23 PM
LANCHBURY JERRY SChief Scientific OfficerAug 03Sale34.0350,0001,701,737232,550Aug 05 05:18 PM
LANGER DENNISDirectorAug 03Sale34.7530,0001,042,50089,527Aug 05 05:11 PM
LANCHBURY JERRY SChief Scientific OfficerJul 13Option Exercise26.4943,2951,146,885272,550Jul 14 05:44 PM
LANCHBURY JERRY SChief Scientific OfficerJul 13Sale33.7443,2951,460,768232,550Jul 14 05:44 PM
LANCHBURY JERRY SChief Scientific OfficerJul 12Option Exercise26.4950,0001,324,500269,255Jul 14 05:44 PM
LANCHBURY JERRY SChief Scientific OfficerJul 12Sale33.5550,0001,677,506232,550Jul 14 05:44 PM
LANCHBURY JERRY SChief Scientific OfficerJul 09Option Exercise24.0150,0001,200,302259,255Jul 12 06:16 PM
LANCHBURY JERRY SChief Scientific OfficerJul 09Sale32.6250,0001,631,037232,550Jul 12 06:16 PM
LANCHBURY JERRY SChief Scientific OfficerJul 07Option Exercise26.4932,308855,839262,974Jul 08 05:50 PM
LANCHBURY JERRY SChief Scientific OfficerJul 07Sale32.2732,3081,042,660232,550Jul 08 05:50 PM
LANCHBURY JERRY SChief Scientific OfficerJun 28Option Exercise25.516,812173,795236,523Jun 30 05:50 PM
LANCHBURY JERRY SChief Scientific OfficerJun 28Sale32.396,812220,608232,550Jun 30 05:50 PM
LANCHBURY JERRY SChief Scientific OfficerJun 25Option Exercise19.4750,000973,500294,562Jun 28 08:00 PM
LANCHBURY JERRY SChief Scientific OfficerJun 25Sale31.9683,3722,664,216232,550Jun 28 08:00 PM
SPIEGELMAN DANIEL KDirectorJun 17Sale30.523,13995,79523,129Jun 17 05:41 PM
SPIEGELMAN DANIEL KDirectorMay 28Sale28.997,142207,02313,420Jun 01 07:15 PM
LANCHBURY JERRY SChief Scientific OfficerMay 04Option Exercise19.4719,360376,939285,282May 05 07:45 PM
LANCHBURY JERRY SChief Scientific OfficerMay 04Sale31.9719,360618,949265,922May 05 07:45 PM
LANCHBURY JERRY SChief Scientific OfficerApr 27Option Exercise19.4740,000778,800305,922Apr 28 05:10 PM
LANCHBURY JERRY SChief Scientific OfficerApr 27Sale31.4740,0001,258,800265,922Apr 28 05:10 PM
Lambert NicoleSee RemarksApr 19Sale27.016,649179,586129,119Apr 20 05:18 PM
Hart Jayne B.Chief People OfficerMar 29Option Exercise22.2758,0001,291,860108,128Mar 30 06:31 PM
Hart Jayne B.Chief People OfficerMar 29Sale30.0058,0001,740,00080,128Mar 30 06:31 PM
LANCHBURY JERRY SChief Scientific OfficerFeb 16Option Exercise18.0080,0001,440,000321,020Feb 17 06:10 PM
LANCHBURY JERRY SChief Scientific OfficerFeb 16Sale29.7180,0002,377,048246,575Feb 17 06:10 PM
Parkinson PaulEVP Strategy and InnovationJan 08Sale25.0011,824295,60076,746Jan 11 04:40 PM
Phanstiel S. LouiseDirectorNov 11Buy16.6215,000249,33666,790Nov 12 08:57 AM
NTLA Intellia Therapeutics, Inc. daily Stock Chart
NTLA [NASD]
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.86 Insider Own1.20% Shs Outstand68.16M Perf Week-4.05%
Market Cap10.62B Forward P/E- EPS next Y-3.26 Insider Trans-64.28% Shs Float66.20M Perf Month-1.06%
Income-185.00M PEG- EPS next Q-0.82 Inst Own82.50% Short Float5.18% Perf Quarter87.23%
Sales41.80M P/S254.06 EPS this Y-13.80% Inst Trans1.00% Short Ratio1.64 Perf Half Y126.56%
Book/sh7.26 P/B20.35 EPS next Y0.60% ROA-29.30% Target Price176.19 Perf Year564.00%
Cash/sh7.36 P/C20.07 EPS next 5Y30.00% ROE-39.00% 52W Range18.81 - 202.73 Perf YTD171.58%
Dividend- P/FCF- EPS past 5Y-46.70% ROI- 52W High-26.25% Beta2.13
Dividend %- Quick Ratio7.40 Sales past 5Y57.20% Gross Margin- 52W Low694.84% ATR9.70
Employees312 Current Ratio7.40 Sales Q/Q-59.50% Oper. Margin- RSI (14)45.56 Volatility5.85% 6.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-66.30% Profit Margin- Rel Volume0.18 Prev Close147.74
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume2.10M Price149.51
Recom2.10 SMA20-5.83% SMA50-1.56% SMA20059.73% Volume120,467 Change1.20%
Jun-28-21Reiterated H.C. Wainwright Buy $111 → $171
Jun-11-21Initiated H.C. Wainwright Buy $111
May-07-21Upgrade ROTH Capital Neutral → Buy $75 → $80
May-04-21Initiated RBC Capital Mkts Outperform $110
Mar-04-21Initiated JMP Securities Mkt Outperform $80
Dec-22-20Downgrade Robert W. Baird Outperform → Neutral $60
Oct-27-20Initiated Truist Buy $40
Oct-14-20Initiated Wells Fargo Overweight
Sep-18-20Initiated Goldman Buy $33
Feb-28-20Upgrade Oppenheimer Perform → Outperform
Feb-14-20Downgrade Wedbush Outperform → Neutral $16
Nov-01-19Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19Initiated Robert W. Baird Outperform $23
Jun-10-19Initiated ROTH Capital Neutral $16
May-03-19Upgrade Wedbush Neutral → Outperform $20 → $21
Apr-12-19Initiated Evercore ISI Outperform
Nov-02-18Downgrade Wedbush Outperform → Neutral $36 → $20
Oct-29-18Initiated Credit Suisse Neutral $24
Sep-21-18Initiated Raymond James Mkt Perform
May-15-18Upgrade Chardan Capital Markets Neutral → Buy $20 → $57.50
Sep-17-21 01:35PM  
Sep-16-21 10:10AM  
07:30AM  
Aug-31-21 07:30AM  
Aug-26-21 12:45PM  
Aug-24-21 10:56AM  
Aug-17-21 10:21AM  
Aug-14-21 08:00AM  
Aug-12-21 08:31AM  
Aug-06-21 08:01PM  
Aug-05-21 03:59PM  
09:01AM  
08:45AM  
07:30AM  
Aug-02-21 08:52AM  
Jul-29-21 03:05PM  
07:30AM  
Jul-27-21 05:50PM  
Jul-16-21 11:02AM  
05:32AM  
Jul-15-21 08:19AM  
Jul-12-21 03:12PM  
Jul-11-21 07:01AM  
Jul-10-21 05:19AM  
Jul-09-21 04:04PM  
Jul-06-21 11:28AM  
Jul-04-21 07:49AM  
Jul-02-21 04:35PM  
04:01PM  
12:48PM  
Jul-01-21 06:56AM  
Jun-30-21 10:14PM  
04:20PM  
04:04PM  
03:30PM  
01:14PM  
12:14PM  
11:32AM  
08:46AM  
06:47AM  
06:42AM  
Jun-29-21 09:08PM  
11:20AM  
09:55AM  
09:34AM  
06:58AM  
05:15AM  
Jun-28-21 04:25PM  
04:12PM  
04:01PM  
02:36PM  
01:17PM  
12:22PM  
12:17PM  
11:09AM  
10:39AM  
10:02AM  
10:00AM  
09:15AM  
08:41AM  
08:39AM  
06:09AM  
05:34AM  
04:52AM  
04:06AM  
03:19AM  
Jun-27-21 07:25AM  
Jun-26-21 08:00PM  
01:07PM  
11:16AM  
Jun-25-21 04:45AM  
Jun-24-21 07:30AM  
Jun-22-21 07:00AM  
06:41AM  
Jun-07-21 07:11AM  
Jun-04-21 07:30AM  
Jun-03-21 07:39AM  
Jun-02-21 09:40AM  
Jun-01-21 03:41AM  
May-11-21 12:12PM  
May-07-21 06:00PM  
May-06-21 08:50AM  
07:30AM  
06:15AM  
Apr-30-21 11:15AM  
Apr-29-21 05:05PM  
07:30AM  
Apr-28-21 05:30AM  
Apr-27-21 04:35PM  
Apr-16-21 03:51PM  
Apr-14-21 12:30PM  
Apr-12-21 07:30AM  
Mar-30-21 07:30AM  
Mar-25-21 07:30AM  
Mar-10-21 07:30AM  
Mar-03-21 01:46AM  
Feb-27-21 09:23AM  
Feb-26-21 12:59AM  
Feb-25-21 09:30PM  
07:30AM  
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Goddard GlennEVP, Chief Financial OfficerSep 07Option Exercise14.583,48250,7683,482Sep 09 05:38 PM
Goddard GlennEVP, Chief Financial OfficerSep 07Sale180.123,482627,1780Sep 09 05:38 PM
LEONARD JOHN MPresident and CEOSep 01Option Exercise21.6244,735967,000764,040Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOSep 01Sale170.0044,7357,604,950719,305Sep 01 08:21 PM
Goddard GlennEVP, Chief Financial OfficerAug 31Option Exercise18.9324,800469,37424,800Sep 01 07:30 PM
LEONARD JOHN MPresident and CEOAug 31Option Exercise14.5837,833551,605757,138Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOAug 31Sale155.0037,8335,864,115719,305Sep 01 08:21 PM
Goddard GlennEVP, Chief Financial OfficerAug 31Sale160.2224,8003,973,4560Sep 01 07:30 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 30Option Exercise12.622,40030,2883,191Sep 01 07:32 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 30Option Exercise14.0197,0001,359,30099,391Sep 01 07:34 PM
Goddard GlennEVP, Chief Financial OfficerAug 30Option Exercise19.275,200100,2045,200Sep 01 07:30 PM
LEONARD JOHN MPresident and CEOAug 30Option Exercise14.2338,804552,031758,109Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOAug 30Sale155.9538,8046,051,353719,305Sep 01 08:21 PM
Goddard GlennEVP, Chief Financial OfficerAug 30Sale155.785,200810,0820Sep 01 07:30 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 30Sale158.042,400379,300791Sep 01 07:32 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 30Sale154.8397,00015,018,0542,391Sep 01 07:34 PM
LEONARD JOHN MPresident and CEOAug 23Option Exercise13.4027,139363,663746,444Aug 25 04:14 PM
LEONARD JOHN MPresident and CEOAug 23Sale152.0127,1394,125,416719,305Aug 25 04:14 PM
LEONARD JOHN MPresident and CEOAug 19Option Exercise13.4022,682303,939741,987Aug 20 06:14 PM
LEONARD JOHN MPresident and CEOAug 19Sale151.2822,6823,431,398719,305Aug 20 06:14 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 09Option Exercise12.622,40030,2883,191Aug 11 04:50 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 09Sale164.052,400393,720791Aug 11 04:50 PM
Goddard GlennEVP, Chief Financial OfficerAug 05Option Exercise19.2720,000385,40020,000Aug 06 06:17 PM
Goddard GlennEVP, Chief Financial OfficerAug 05Sale151.0520,0003,021,0560Aug 06 06:17 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 04Option Exercise13.4026,000348,40028,391Aug 06 06:19 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 04Sale138.2426,0003,594,3572,391Aug 06 06:19 PM
FORMELA JEAN FRANCOISDirectorJun 28Sale132.73553,37673,448,87910,000Jun 29 09:48 AM
FORMELA JEAN FRANCOISDirectorJun 14Sale87.37170,77914,921,294563,376Jun 15 09:51 AM
FORMELA JEAN FRANCOISDirectorJun 11Sale85.2330,9462,637,480734,155Jun 15 09:51 AM
FORMELA JEAN FRANCOISDirectorApr 29Sale85.434,513385,546765,101Apr 30 08:55 PM
FORMELA JEAN FRANCOISDirectorApr 28Sale85.56131,92611,287,893769,614Apr 28 07:51 PM
FORMELA JEAN FRANCOISDirectorApr 27Sale86.22210,23018,125,992901,540Apr 28 07:51 PM
FORMELA JEAN FRANCOISDirectorApr 26Sale84.9380668,4541,111,770Apr 28 07:51 PM
LEONARD JOHN MPresident and CEOApr 13Option Exercise11.1625,937289,506719,305Apr 15 08:50 PM
DORSA CAROLINEDirectorApr 05Option Exercise6.407,50048,00012,910Apr 06 06:09 PM
FORMELA JEAN FRANCOISDirectorApr 05Sale84.9880067,9841,112,576Apr 07 02:14 PM
DORSA CAROLINEDirectorApr 05Sale82.197,500616,4055,410Apr 06 06:09 PM
Rivera Jose EEVP, General CounselApr 01Option Exercise12.5197,0011,213,537178,077Apr 02 08:42 PM
LEONARD JOHN MPresident and CEOApr 01Option Exercise14.1571,0411,005,049707,263Apr 02 08:46 PM
LEONARD JOHN MPresident and CEOApr 01Sale83.6438,2093,195,661681,222Apr 02 08:46 PM
Rivera Jose EEVP, General CounselApr 01Sale82.4650,4554,160,559131,032Apr 02 08:42 PM
FORMELA JEAN FRANCOISDirectorFeb 26Sale60.29501,94530,262,7161,113,376Mar 01 01:59 PM
LEONARD JOHN MPresident and CEOFeb 09Option Exercise6.8356,718387,384688,579Feb 09 08:36 PM
Rivera Jose EEVP, General CounselFeb 09Option Exercise18.3021,000384,195129,409Feb 09 08:38 PM
Rivera Jose EEVP, General CounselFeb 09Sale75.0011,489861,675117,920Feb 09 08:38 PM
LEONARD JOHN MPresident and CEOFeb 09Sale75.0028,0432,103,225660,536Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 05Option Exercise13.4040,000536,000654,803Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 05Sale67.6622,9421,552,185631,861Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 03Option Exercise17.68117,0602,069,793651,661Feb 03 09:39 PM
LEONARD JOHN MPresident and CEOFeb 03Sale72.5467,8564,922,490584,601Feb 03 09:39 PM
Rivera Jose EEVP, General CounselFeb 01Option Exercise9.68109,0001,054,620121,686Feb 03 09:38 PM
LEONARD JOHN MPresident and CEOFeb 01Option Exercise13.69200,0002,737,600598,814Feb 03 09:39 PM
Rivera Jose EEVP, General CounselFeb 01Sale63.9954,6593,497,90288,686Feb 03 09:38 PM
LEONARD JOHN MPresident and CEOFeb 01Sale64.00109,8897,032,905523,853Feb 03 09:39 PM
Cohen Fred EDirectorJan 20Option Exercise13.7820,000275,60030,000Jan 22 04:22 PM
Rivera Jose EEVP, General CounselJan 05Sale55.862,078116,07751,990Jan 05 08:55 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerJan 05Sale55.861,37776,91916,656Jan 05 08:58 PM
LEONARD JOHN MPresident and CEOJan 05Sale55.866,239348,511475,488Jan 05 09:24 PM
LEONARD JOHN MPresident and CEODec 31Option Exercise0.0014,3750481,727Jan 05 09:24 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerDec 31Option Exercise0.004,792018,033Jan 05 08:58 PM
Rivera Jose EEVP, General CounselDec 31Option Exercise0.004,792054,068Jan 05 08:55 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerDec 30Option Exercise13.481,50020,22012,673Jan 04 09:03 PM
KARSEN PERRY ADirectorDec 17Option Exercise18.4588,7641,637,84293,764Dec 18 04:29 PM
KARSEN PERRY ADirectorDec 17Sale53.5588,7644,753,6805,000Dec 18 04:29 PM
Rivera Jose EEVP, General CounselDec 01Option Exercise13.885,00069,40052,072Dec 03 06:42 PM
Rivera Jose EEVP, General CounselDec 01Sale38.213,364128,52548,708Dec 03 06:42 PM
LEONARD JOHN MPresident and CEONov 27Option Exercise16.1735,000566,100487,352Nov 27 09:00 PM
LEONARD JOHN MPresident and CEONov 27Sale38.5735,0001,350,000467,352Nov 27 09:00 PM
LEONARD JOHN MPresident and CEONov 25Option Exercise6.8350,000341,500517,352Nov 25 08:02 PM
LEONARD JOHN MPresident and CEONov 25Sale36.0050,0001,800,000467,352Nov 25 08:02 PM
Rivera Jose EEVP, General CounselNov 18Option Exercise18.3084815,51847,696Nov 18 07:55 PM
Rivera Jose EEVP, General CounselNov 18Sale35.0062421,84047,072Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 16Option Exercise14.5820,000291,600487,352Nov 18 07:56 PM
Rivera Jose EEVP, General CounselNov 16Option Exercise7.4410,56278,58552,315Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 16Sale34.0020,000680,000467,352Nov 18 07:56 PM
Rivera Jose EEVP, General CounselNov 16Sale34.296,029206,72846,700Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 04Option Exercise6.8350,000341,500517,352Nov 06 04:38 PM
Rivera Jose EEVP, General CounselNov 04Option Exercise13.885,00069,40045,679Nov 06 04:41 PM
Rivera Jose EEVP, General CounselNov 04Sale28.003,36494,19242,315Nov 06 04:41 PM
LEONARD JOHN MPresident and CEONov 04Sale26.0050,0001,300,000467,352Nov 06 04:38 PM
Rivera Jose EEVP, General CounselOct 15Option Exercise6.8310,00068,30046,294Oct 16 08:58 PM
Rivera Jose EEVP, General CounselOct 15Sale24.205,615135,88340,679Oct 16 08:58 PM
LEONARD JOHN MPresident and CEOOct 07Option Exercise6.835,00034,150472,352Oct 09 04:14 PM
LEONARD JOHN MPresident and CEOOct 07Sale21.835,000109,150467,352Oct 09 04:14 PM
LNTH Lantheus Holdings, Inc. daily Stock Chart
LNTH [NASD]
Lantheus Holdings, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own2.20% Shs Outstand67.50M Perf Week5.66%
Market Cap1.76B Forward P/E28.02 EPS next Y0.93 Insider Trans-4.05% Shs Float65.68M Perf Month3.92%
Income-27.40M PEG- EPS next Q0.06 Inst Own99.60% Short Float4.31% Perf Quarter1.72%
Sales376.30M P/S4.67 EPS this Y-131.50% Inst Trans4.78% Short Ratio5.87 Perf Half Y27.49%
Book/sh7.53 P/B3.45 EPS next Y137.69% ROA-3.20% Target Price32.00 Perf Year108.26%
Cash/sh1.35 P/C19.22 EPS next 5Y37.73% ROE-5.30% 52W Range10.52 - 28.74 Perf YTD92.51%
Dividend- P/FCF54.78 EPS past 5Y16.20% ROI-0.80% 52W High-8.79% Beta1.43
Dividend %- Quick Ratio2.10 Sales past 5Y3.00% Gross Margin43.70% 52W Low149.15% ATR0.85
Employees595 Current Ratio2.50 Sales Q/Q53.20% Oper. Margin-4.30% RSI (14)54.28 Volatility3.14% 3.10%
OptionableYes Debt/Eq0.35 EPS Q/Q-142.90% Profit Margin-7.30% Rel Volume0.28 Prev Close25.97
ShortableYes LT Debt/Eq0.33 EarningsJul 28 BMO Payout- Avg Volume482.45K Price26.21
Recom1.30 SMA201.47% SMA501.53% SMA20021.58% Volume43,424 Change0.93%
Feb-01-21Initiated SVB Leerink Outperform $24
Jun-29-20Resumed Jefferies Buy $29
Aug-16-19Upgrade CJS Securities Market Perform → Market Outperform
Nov-02-17Upgrade Wells Fargo Market Perform → Outperform
Nov-08-16Reiterated RBC Capital Mkts Outperform $6 → $12
Sep-23-16Resumed Credit Suisse Neutral
Feb-24-16Reiterated RBC Capital Mkts Outperform $9 → $6
Dec-11-15Downgrade Credit Suisse Outperform → Neutral
Sep-30-15Downgrade Wells Fargo Outperform → Market Perform
Jul-20-15Initiated Wells Fargo Outperform
Jul-20-15Initiated Robert W. Baird Outperform $10
Jul-20-15Initiated RBC Capital Mkts Outperform $10
Jul-20-15Initiated Jefferies Buy $12
Jul-20-15Initiated Credit Suisse Outperform $10
Sep-13-21 08:00AM  
07:30AM  
Sep-10-21 08:30AM  
Sep-02-21 08:00AM  
Jul-29-21 06:25PM  
Jul-28-21 04:30PM  
08:25AM  
07:00AM  
Jul-21-21 03:02PM  
Jul-20-21 06:38AM  
Jul-14-21 08:00AM  
Jun-14-21 08:30AM  
May-28-21 06:17AM  
May-27-21 11:45AM  
08:54AM  
07:05AM  
07:00AM  
May-24-21 09:39AM  
May-21-21 08:30AM  
May-20-21 08:30AM  
May-04-21 02:00PM  
08:20AM  
07:00AM  
06:15AM  
May-03-21 08:30AM  
Apr-30-21 08:30AM  
Apr-21-21 04:21AM  
Apr-20-21 08:30AM  
Apr-07-21 08:30AM  
Apr-01-21 08:30AM  
Mar-30-21 12:44PM  
08:29AM  
Mar-23-21 09:09AM  
Mar-22-21 08:30AM  
Mar-01-21 08:30AM  
Feb-26-21 09:30AM  
Feb-25-21 04:41PM  
04:01PM  
02:30PM  
Feb-12-21 08:30AM  
Feb-11-21 04:30PM  
Feb-08-21 08:27AM  
04:31AM  
Feb-06-21 09:15AM  
Feb-04-21 08:30AM  
Jan-12-21 08:30AM  
Dec-15-20 05:29PM  
Dec-09-20 02:19PM  
09:35AM  
08:30AM  
Dec-03-20 07:00AM  
Nov-24-20 08:00AM  
Nov-19-20 08:17AM  
Nov-18-20 04:01PM  
Nov-13-20 08:30AM  
Nov-09-20 04:30PM  
Nov-05-20 03:00PM  
10:25AM  
07:00AM  
06:15AM  
Nov-04-20 08:00AM  
Nov-02-20 11:18AM  
Oct-29-20 12:34PM  
08:30AM  
Oct-22-20 12:33PM  
07:30AM  
Oct-12-20 12:58PM  
Oct-08-20 08:25AM  
Sep-30-20 08:00AM  
Sep-03-20 08:00AM  
Aug-12-20 08:00AM  
Jul-30-20 12:00PM  
07:00AM  
Jul-29-20 03:06PM  
Jul-28-20 10:25AM  
Jul-23-20 08:00AM  
Jul-01-20 08:00AM  
Jun-22-20 12:11PM  
07:00AM  
Jun-17-20 05:33PM  
Jun-16-20 04:05PM  
08:30AM  
May-27-20 07:53PM  
May-20-20 04:30PM  
May-05-20 04:30PM  
May-01-20 07:31PM  
Apr-30-20 06:30PM  
07:39AM  
07:00AM  
Apr-16-20 08:30AM  
Apr-14-20 11:17AM  
Apr-09-20 08:30AM  
Apr-06-20 08:30AM  
Apr-04-20 10:15AM  
Apr-02-20 02:58PM  
08:30AM  
Mar-17-20 07:58AM  
Feb-28-20 07:06AM  
Feb-27-20 02:10PM  
Feb-26-20 09:36AM  
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sabens AndreaChief Accounting OfficerSep 15Sale24.551,24230,49166,070Sep 17 04:30 PM
Montagut EtienneChief Business OfficerSep 08Sale26.0645711,90987,262Sep 10 04:30 PM
Sabens AndreaChief Accounting OfficerAug 16Sale25.461,24231,62167,312Aug 18 05:10 PM
Heino Mary AnnePresident & CEOAug 10Sale25.8315,580402,369688,182Aug 12 04:30 PM
Bolla John J.Chief Operations OfficerJun 16Sale24.372,25354,912102,440Jun 21 04:31 PM
Montagut EtienneChief Business OfficerJun 04Sale24.607,435182,90187,719Jun 08 04:30 PM
DUFFY MICHAEL PSVP and General CounselApr 16Sale21.757,500163,125109,472Apr 20 04:30 PM
Heino Mary AnnePresident & CEOApr 12Sale20.6619,421401,277703,762Apr 14 04:30 PM
McHugh JulieDirectorApr 09Sale21.222,80059,41623,057Apr 13 04:30 PM
LENO SAM RDirectorApr 08Sale21.175,000105,84040,784Apr 12 04:30 PM
DUFFY MICHAEL PSVP and General CounselMar 08Sale19.165,03296,418116,972Mar 08 09:05 PM
Maeusli Heinz ChristophDirectorMar 05Buy18.601,00018,60016,211Mar 09 09:07 PM
Heino Mary AnnePresident & CEOMar 05Sale18.2627,157495,838711,720Mar 09 09:06 PM
Blanchfield PaulChief Commercial OfficerMar 04Sale18.404,06174,72226,509Mar 08 09:09 PM
Bolla John J.Chief Operations OfficerMar 04Sale18.401,88734,72157,345Mar 08 09:07 PM
DUFFY MICHAEL PSVP and General CounselMar 04Sale18.401,73731,96194,948Mar 08 09:05 PM
Marshall Robert J. Jr.CFO and TreasurerMar 04Sale18.402,28041,95276,985Mar 08 08:48 PM
Molnar IstvanChief Medical OfficerMar 04Sale18.404,02774,09725,130Mar 08 08:40 PM
Marshall Robert J. Jr.CFO and TreasurerMar 01Sale19.081,46527,95579,265Mar 03 04:30 PM
Bolla John J.Chief Operations OfficerMar 01Sale19.081,18722,65059,232Mar 03 04:30 PM
DUFFY MICHAEL PSVP and General CounselMar 01Sale19.081,47328,108101,929Mar 03 04:30 PM
Maeusli Heinz ChristophDirectorFeb 26Buy18.021,00018,02015,211Mar 02 04:30 PM
Maeusli Heinz ChristophDirectorFeb 19Buy19.391,00019,39014,211Feb 23 04:30 PM
Maeusli Heinz ChristophDirectorFeb 12Buy20.031,00020,03013,211Feb 17 04:30 PM
Maeusli Heinz ChristophDirectorFeb 05Buy17.941,00017,94012,211Feb 09 04:30 PM
Maeusli Heinz ChristophDirectorJan 29Buy16.131,00016,13011,211Feb 02 04:30 PM
Maeusli Heinz ChristophDirectorJan 22Buy15.291,00015,29010,211Jan 26 04:30 PM
Maeusli Heinz ChristophDirectorJan 15Buy15.801,00015,8009,211Jan 20 04:30 PM
DUFFY MICHAEL PSVP and General CounselDec 09Sale14.0015,000210,000103,402Dec 11 04:30 PM
Marshall Robert J. Jr.CFO and TreasurerOct 16Sale13.205,04466,57180,730Oct 20 04:30 PM
DUFFY MICHAEL PSVP and General CounselOct 06Sale14.0015,000210,000118,402Oct 08 04:30 PM
HSKA Heska Corporation daily Stock Chart
HSKA [NASD]
Heska Corporation
Index- P/E- EPS (ttm)-0.17 Insider Own0.90% Shs Outstand10.17M Perf Week-1.20%
Market Cap2.62B Forward P/E214.49 EPS next Y1.18 Insider Trans-14.62% Shs Float10.05M Perf Month-5.60%
Income-1.50M PEG- EPS next Q-0.15 Inst Own98.70% Short Float3.09% Perf Quarter11.42%
Sales246.40M P/S10.62 EPS this Y-745.80% Inst Trans2.15% Short Ratio5.36 Perf Half Y46.18%
Book/sh42.66 P/B5.91 EPS next Y895.76% ROA-0.30% Target Price287.00 Perf Year159.82%
Cash/sh23.62 P/C10.67 EPS next 5Y25.00% ROE-0.40% 52W Range95.46 - 275.94 Perf YTD73.04%
Dividend- P/FCF139.90 EPS past 5Y-33.50% ROI-2.50% 52W High-7.62% Beta1.72
Dividend %- Quick Ratio7.00 Sales past 5Y13.50% Gross Margin41.70% 52W Low167.04% ATR8.83
Employees602 Current Ratio8.00 Sales Q/Q42.00% Oper. Margin0.50% RSI (14)46.99 Volatility3.17% 3.24%
OptionableYes Debt/Eq0.19 EPS Q/Q92.30% Profit Margin-0.60% Rel Volume0.53 Prev Close252.03
ShortableYes LT Debt/Eq0.19 EarningsAug 03 BMO Payout- Avg Volume57.95K Price254.91
Recom2.20 SMA20-2.64% SMA50-1.00% SMA20026.12% Volume9,813 Change1.14%
Jul-12-21Upgrade Guggenheim Neutral → Buy $280
Oct-21-20Upgrade Raymond James Mkt Perform → Outperform $125
Aug-05-20Upgrade Piper Sandler Neutral → Overweight $87 → $110
Nov-07-19Downgrade Raymond James Outperform → Mkt Perform
Sep-18-19Initiated Piper Jaffray Neutral $68
May-23-19Initiated Guggenheim Neutral
Jul-19-18Resumed The Benchmark Company Buy $120
May-18-18Reiterated Canaccord Genuity Buy $100 → $115
May-18-18Reiterated B. Riley FBR, Inc. Neutral $77 → $93
May-07-18Reiterated The Benchmark Company Buy $90 → $100
Mar-01-18Reiterated B. Riley FBR, Inc. Neutral $93 → $77
Feb-05-18Upgrade Sidoti Neutral → Buy $94
Nov-03-17Reiterated B. Riley FBR, Inc. Neutral $96.50 → $93
Aug-03-17Reiterated The Benchmark Company Buy $106 → $120
Mar-01-17Reiterated The Benchmark Company Buy $100 → $106
Jan-26-17Downgrade CL King Buy → Neutral
Nov-29-16Initiated The Benchmark Company Buy $78
Aug-04-16Downgrade Gabelli & Co Buy → Hold
Jul-01-16Initiated Sidoti Buy
Apr-01-16Initiated CL King Buy
Sep-09-21 08:00AM  
Sep-08-21 08:00AM  
Aug-12-21 01:06PM  
Aug-03-21 06:00PM  
08:00AM  
Jul-26-21 04:12AM  
Jul-14-21 10:40AM  
Jul-13-21 11:11AM  
08:00AM  
Jun-11-21 03:55AM  
Jun-09-21 08:11AM  
May-25-21 08:00AM  
May-06-21 11:00PM  
09:25AM  
08:00AM  
Apr-27-21 03:47AM  
Apr-19-21 12:42PM  
Apr-16-21 08:00AM  
Apr-08-21 08:00AM  
Apr-01-21 06:25AM  
Mar-06-21 06:40AM  
Mar-02-21 10:00PM  
Mar-01-21 04:05PM  
Feb-25-21 11:22PM  
Feb-24-21 02:53AM  
Feb-23-21 03:31PM  
09:26AM  
08:45AM  
08:00AM  
Feb-16-21 08:00AM  
Feb-04-21 02:29AM  
Jan-26-21 08:00AM  
Jan-13-21 08:00AM  
Jan-12-21 04:30PM  
Jan-05-21 08:30AM  
Dec-21-20 01:37AM  
Dec-15-20 10:29PM  
Nov-24-20 08:00AM  
Nov-18-20 08:00AM  
Nov-05-20 03:01PM  
10:45AM  
08:00AM  
Oct-29-20 12:35PM  
Oct-15-20 08:00AM  
Oct-08-20 08:00AM  
Sep-23-20 03:37PM  
Sep-22-20 10:09AM  
Aug-24-20 08:30AM  
Aug-05-20 12:00AM  
Jul-28-20 12:32PM  
Jul-24-20 10:51AM  
Jul-16-20 08:00AM  
Jun-28-20 04:20PM  
Jun-15-20 09:26AM  
May-08-20 12:31AM  
May-07-20 09:25AM  
08:32AM  
08:00AM  
Apr-30-20 12:33PM  
Apr-22-20 08:00AM  
Apr-16-20 08:00AM  
Apr-01-20 09:00AM  
Mar-25-20 08:00AM  
Mar-23-20 05:58PM  
Mar-17-20 07:57AM  
Mar-04-20 11:10AM  
Mar-03-20 07:30AM  
Feb-25-20 09:55AM  
08:00AM  
Feb-18-20 08:00AM  
Jan-31-20 09:54AM  
Jan-14-20 04:05PM  
Jan-09-20 08:00AM  
Dec-20-19 08:00AM  
Dec-19-19 06:08PM  
Dec-12-19 11:31PM  
Dec-04-19 10:43AM  
Nov-14-19 08:00AM  
Nov-05-19 09:15AM  
08:00AM  
Oct-30-19 05:20PM  
Oct-29-19 10:33AM  
Oct-28-19 10:52AM  
Oct-15-19 08:00AM  
Oct-07-19 02:15PM  
Sep-16-19 10:40AM  
Sep-12-19 09:40PM  
Sep-11-19 04:01PM  
Aug-29-19 08:00AM  
Aug-28-19 04:00AM  
Aug-26-19 09:23AM  
Aug-06-19 11:24PM  
08:00AM  
Aug-05-19 02:48PM  
Jul-17-19 08:00AM  
Jul-16-19 08:00AM  
Jul-10-19 02:52PM  
Jun-28-19 07:30PM  
Jun-13-19 08:00AM  
Jun-09-19 09:11AM  
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wisnewski NancyChief Operating OfficerAug 18Sale270.331,000270,33154,505Aug 19 03:42 PM
Larson Sharon J.DirectorAug 17Option Exercise28.412,00056,8209,501Aug 19 03:37 PM
Larson Sharon J.DirectorAug 17Sale266.832,000533,6517,501Aug 19 03:37 PM
Grassman CatherineEVP, CFOAug 06Option Exercise69.775,000348,8508,986Aug 09 04:20 PM
Grassman CatherineEVP, CFOAug 06Sale260.245,0001,301,2103,986Aug 09 04:20 PM
Wisnewski NancyChief Operating OfficerJun 04Sale197.875,000989,32655,505Jun 07 05:10 PM
Larson Sharon J.DirectorMay 24Option Exercise28.413,00085,23010,501May 25 12:35 PM
Larson Sharon J.DirectorMay 24Sale205.003,000615,0007,501May 25 12:35 PM
Wisnewski NancyChief Operating OfficerApr 30Option Exercise6.767,50050,70060,505May 03 05:13 PM
Wisnewski NancyChief Operating OfficerDec 28Option Exercise4.966,00029,76051,874Dec 30 01:20 PM
Wisnewski NancyChief Operating OfficerDec 09Sale140.3850070,19145,874Dec 10 12:57 PM
Wisnewski NancyChief Operating OfficerDec 08Sale133.1435046,59846,374Dec 09 02:41 PM
Wisnewski NancyChief Operating OfficerDec 07Sale131.0015019,65046,724Dec 09 02:41 PM
Aroesty Jason DEVP, International DiagnosticsNov 27Option Exercise106.6713,3341,422,33813,334Nov 30 03:56 PM
Aroesty Jason DEVP, International DiagnosticsNov 27Sale126.8613,3341,691,5170Nov 30 03:56 PM
Wisnewski NancyChief Operating OfficerNov 18Sale129.5050064,75046,874Nov 18 03:51 PM
Wisnewski NancyChief Operating OfficerNov 16Sale126.501,000126,50047,374Nov 18 03:51 PM
Trowbridge Bonnie J.DirectorNov 09Option Exercise33.764,917165,9819,006Nov 12 10:19 AM
Trowbridge Bonnie J.DirectorNov 09Sale125.474,917616,9594,089Nov 12 10:19 AM
Wilson Kevin S.CEO and PresidentOct 21Sale110.2813,4211,480,0370Oct 21 05:48 PM
Wilson Kevin S.CEO and PresidentOct 08Sale109.003,129341,0613,086Oct 09 03:35 PM
VNRX VolitionRx Limited daily Stock Chart
VNRX [AMEX]
VolitionRx Limited
Index- P/E- EPS (ttm)-0.42 Insider Own3.30% Shs Outstand52.95M Perf Week0.33%
Market Cap163.70M Forward P/E- EPS next Y-0.45 Insider Trans8.81% Shs Float34.92M Perf Month-1.28%
Income-21.10M PEG- EPS next Q-0.11 Inst Own12.30% Short Float2.59% Perf Quarter1.32%
Sales0.06M P/S2822.11 EPS this Y-9.40% Inst Trans-26.01% Short Ratio5.22 Perf Half Y-20.21%
Book/sh0.50 P/B6.16 EPS next Y2.20% ROA-66.00% Target Price- Perf Year0.98%
Cash/sh0.52 P/C5.87 EPS next 5Y- ROE-90.50% 52W Range2.85 - 6.67 Perf YTD-20.82%
Dividend- P/FCF- EPS past 5Y3.50% ROI- 52W High-53.82% Beta1.82
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low8.07% ATR0.13
Employees65 Current Ratio5.40 Sales Q/Q377.10% Oper. Margin- RSI (14)41.65 Volatility2.90% 3.80%
OptionableYes Debt/Eq0.15 EPS Q/Q10.00% Profit Margin- Rel Volume0.39 Prev Close3.08
ShortableYes LT Debt/Eq0.12 EarningsAug 12 BMO Payout- Avg Volume173.42K Price3.08
Recom2.00 SMA20-4.88% SMA50-2.96% SMA200-15.21% Volume21,506 Change0.00%
Mar-10-21Initiated Cantor Fitzgerald Overweight $8
May-16-18Initiated Maxim Group Buy $6
May-14-18Reiterated The Benchmark Company Buy $7 → $5
Sep-07-16Reiterated Rodman & Renshaw Buy $12 → $10
Feb-01-16Initiated Rodman & Renshaw Buy $12
Sep-20-21 08:35AM  
Sep-10-21 08:35AM  
Aug-18-21 11:37AM  
08:45AM  
Aug-16-21 08:30AM  
Aug-12-21 05:00PM  
09:00AM  
Aug-11-21 04:10PM  
Aug-04-21 08:15AM  
Jul-22-21 08:00AM  
Jun-28-21 08:35AM  
Jun-22-21 09:58PM  
04:45PM  
Jun-21-21 08:35AM  
08:35AM  
May-20-21 12:25PM  
May-18-21 05:30PM  
May-12-21 06:15AM  
May-11-21 04:10PM  
May-06-21 09:00AM  
08:15AM  
Apr-19-21 09:00AM  
Mar-31-21 08:30AM  
Mar-30-21 08:30AM  
Mar-29-21 04:10PM  
08:35AM  
Mar-23-21 07:30PM  
06:15AM  
Mar-22-21 04:10PM  
08:35AM  
Mar-19-21 04:24PM  
08:35AM  
Mar-17-21 08:00AM  
Mar-16-21 08:30AM  
Mar-08-21 04:15PM  
Feb-19-21 06:03AM  
Feb-17-21 09:00AM  
Feb-12-21 09:25AM  
Feb-10-21 09:18AM  
Feb-09-21 04:01PM  
Feb-08-21 08:35AM  
Feb-02-21 07:45AM  
Feb-01-21 03:29PM  
02:25PM  
Jan-28-21 08:35AM  
06:15AM  
Jan-25-21 08:45AM  
Jan-15-21 04:55AM  
Jan-13-21 07:00AM  
Jan-06-21 08:25AM  
Dec-14-20 08:29AM  
Dec-04-20 09:30AM  
Dec-03-20 08:30AM  
Dec-01-20 08:45AM  
Nov-24-20 09:30AM  
Nov-19-20 07:00AM  
06:45AM  
Nov-16-20 06:16AM  
Nov-12-20 04:10PM  
Nov-10-20 08:00AM  
Nov-09-20 08:00AM  
Oct-21-20 08:00AM  
Oct-20-20 07:00AM  
Oct-14-20 08:00AM  
Oct-12-20 08:00AM  
Sep-29-20 08:00AM  
Sep-21-20 08:35AM  
Sep-17-20 03:43PM  
Sep-14-20 08:35AM  
Sep-01-20 08:00AM  
Aug-31-20 05:00PM  
Aug-20-20 03:30PM  
Aug-18-20 05:15AM  
Aug-13-20 04:10PM  
Aug-10-20 07:30AM  
Aug-05-20 08:12AM  
Aug-04-20 04:09PM  
Jul-30-20 10:00AM  
Jul-16-20 11:00AM  
Jul-14-20 06:00AM  
Jul-09-20 09:00AM  
Jun-25-20 08:45AM  
Jun-10-20 09:34AM  
May-27-20 08:45AM  
May-22-20 04:01PM  
May-20-20 08:45AM  
May-19-20 04:01PM  
08:18AM  
May-13-20 05:00PM  
May-07-20 04:10PM  
May-05-20 08:30AM  
May-04-20 02:43PM  
Apr-29-20 08:30AM  
Apr-23-20 08:30AM  
Mar-28-20 10:53AM  
Mar-10-20 08:45AM  
Mar-03-20 08:30AM  
Feb-18-20 04:10PM  
08:30AM  
Feb-12-20 01:36PM  
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TERRELL JASON BRADLEY MDChief Medical OfficerMay 28Sale3.5410,00035,40024,949Jun 02 04:36 PM
Innes Guy ArchibaldDirectorMay 17Buy3.4750,000173,5001,534,975May 18 11:37 AM
Innes Guy ArchibaldDirectorMay 14Buy3.29100,000329,0001,484,975May 18 11:37 AM
Nguyen KimDirectorMay 14Buy3.202,0006,4002,500May 18 11:40 AM
TERRELL JASON BRADLEY MDChief Medical OfficerFeb 05Sale5.3710,00053,70034,949Feb 08 04:06 PM
TERRELL JASON BRADLEY MDChief Medical OfficerDec 02Sale3.4010,00034,00044,949Dec 04 04:16 PM
TERRELL JASON BRADLEY MDChief Medical OfficerNov 18Sale3.363,42911,50754,949Nov 19 04:21 PM
TERRELL JASON BRADLEY MDChief Medical OfficerNov 17Sale3.401,5715,34158,378Nov 19 04:21 PM
IDXX IDEXX Laboratories, Inc. daily Stock Chart
IDXX [NASD]
IDEXX Laboratories, Inc.
IndexS&P 500 P/E79.54 EPS (ttm)8.38 Insider Own0.90% Shs Outstand85.33M Perf Week0.83%
Market Cap56.88B Forward P/E71.34 EPS next Y9.35 Insider Trans-10.99% Shs Float84.27M Perf Month-2.24%
Income727.80M PEG4.62 EPS next Q1.89 Inst Own87.80% Short Float1.25% Perf Quarter9.03%
Sales3.05B P/S18.67 EPS this Y37.30% Inst Trans0.28% Short Ratio2.66 Perf Half Y36.75%
Book/sh8.76 P/B76.13 EPS next Y11.72% ROA32.10% Target Price717.50 Perf Year82.85%
Cash/sh2.72 P/C245.08 EPS next 5Y17.22% ROE115.40% 52W Range359.21 - 706.95 Perf YTD33.41%
Dividend- P/FCF81.93 EPS past 5Y26.70% ROI39.90% 52W High-5.45% Beta0.93
Dividend %- Quick Ratio1.20 Sales past 5Y11.10% Gross Margin58.80% 52W Low86.08% ATR14.74
Employees9300 Current Ratio1.50 Sales Q/Q29.60% Oper. Margin28.40% RSI (14)48.44 Volatility1.85% 2.30%
OptionableYes Debt/Eq1.21 EPS Q/Q35.60% Profit Margin23.90% Rel Volume0.57 Prev Close666.87
ShortableYes LT Debt/Eq1.04 EarningsJul 30 BMO Payout0.00% Avg Volume394.55K Price668.41
Recom2.40 SMA20-0.68% SMA50-1.25% SMA20018.46% Volume72,277 Change0.23%
Aug-05-21Resumed Credit Suisse Outperform $735
Jul-12-21Downgrade Guggenheim Buy → Neutral
Feb-17-21Initiated Barclays Overweight $600
Sep-09-19Initiated Goldman Neutral $277
May-23-19Initiated Guggenheim Buy $276
Nov-02-18Reiterated BofA/Merrill Buy $275 → $235
May-07-18Reiterated Stifel Buy $215 → $225
Jan-16-18Initiated Piper Jaffray Overweight $200
Aug-23-17Upgrade BofA/Merrill Neutral → Buy
Jul-28-17Upgrade CL King Neutral → Buy
Feb-03-17Downgrade Feltl & Co. Hold → Sell
Sep-29-16Resumed BofA/Merrill Neutral
Aug-16-16Reiterated Stifel Buy $120 → $125
Aug-03-16Upgrade Northcoast Sell → Neutral
Jul-20-16Reiterated Canaccord Genuity Buy $90 → $98
Apr-19-16Reiterated Canaccord Genuity Buy $80 → $85
Apr-01-16Initiated CL King Neutral
Mar-21-16Reiterated Stifel Buy $80 → $85
Feb-04-16Initiated Credit Suisse Outperform
Oct-29-15Reiterated Stifel Buy $85 → $80
Sep-21-21 10:36AM  
Sep-20-21 08:29AM  
Sep-17-21 09:25AM  
Sep-16-21 12:50PM  
Sep-15-21 06:27AM  
Sep-10-21 11:30AM  
Sep-07-21 10:37AM  
10:27AM  
Aug-30-21 01:32PM  
12:45PM  
10:53AM  
08:14AM  
Aug-28-21 08:00AM  
Aug-27-21 04:34PM  
12:55PM  
09:19AM  
09:18AM  
Aug-24-21 11:30AM  
Aug-20-21 06:57PM  
Aug-18-21 09:33AM  
08:18AM  
06:35AM  
Aug-17-21 11:47AM  
10:13AM  
08:56AM  
Aug-11-21 12:45PM  
Aug-10-21 09:53AM  
Aug-09-21 03:30PM  
Aug-05-21 11:30AM  
Jul-30-21 02:30PM  
09:55AM  
07:45AM  
06:30AM  
Jul-29-21 09:13AM  
Jul-28-21 06:20AM  
Jul-27-21 07:28AM  
Jul-23-21 03:00PM  
Jul-22-21 05:55AM  
Jul-20-21 12:10PM  
08:04AM  
Jul-19-21 08:30AM  
03:48AM  
Jul-07-21 09:02AM  
Jul-06-21 08:13AM  
Jul-05-21 07:51AM  
Jun-30-21 04:05PM  
Jun-29-21 07:29AM  
06:48AM  
Jun-25-21 07:12AM  
Jun-24-21 10:28AM  
06:53AM  
Jun-23-21 11:30AM  
09:43AM  
07:42AM  
Jun-22-21 10:03AM  
Jun-21-21 11:32AM  
08:30AM  
Jun-18-21 07:43AM  
Jun-15-21 07:32AM  
Jun-14-21 10:38AM  
Jun-11-21 05:45PM  
10:41AM  
Jun-10-21 10:25AM  
Jun-09-21 08:12AM  
08:11AM  
Jun-08-21 10:14AM  
07:11AM  
06:59AM  
Jun-07-21 05:50PM  
07:40AM  
Jun-04-21 11:30AM  
08:21AM  
04:12AM  
Jun-03-21 11:31AM  
08:47AM  
Jun-02-21 04:53PM  
04:25PM  
06:27AM  
May-28-21 04:19PM  
04:06PM  
May-26-21 11:45AM  
May-25-21 04:27PM  
11:52AM  
May-19-21 08:00AM  
May-13-21 01:00PM  
May-12-21 11:39AM  
May-10-21 05:27PM  
09:25AM  
May-05-21 10:09AM  
07:20AM  
May-04-21 04:16PM  
04:00PM  
11:45AM  
11:29AM  
07:50AM  
06:45AM  
06:30AM  
May-03-21 08:22AM  
Apr-30-21 05:50PM  
Apr-27-21 08:17AM  
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Turner Kathy VSenior Vice PresidentAug 31Option Exercise79.541,25699,9024,131Sep 02 05:03 PM
Turner Kathy VSenior Vice PresidentAug 30Option Exercise79.542,250178,9655,125Aug 31 05:01 PM
Turner Kathy VSenior Vice PresidentAug 30Sale687.222,2501,546,2502,875Aug 31 05:01 PM
Turner Kathy VSenior Vice PresidentAug 27Option Exercise64.2427617,7303,151Aug 31 05:01 PM
Turner Kathy VSenior Vice PresidentAug 27Sale678.00276187,1282,875Aug 31 05:01 PM
MAZELSKY JONATHAN JAYPresident & CEOAug 16Sale673.331,263850,41149,427Aug 17 05:02 PM
MAZELSKY JONATHAN JAYPresident & CEOAug 13Sale675.714,7373,200,85250,690Aug 17 05:02 PM
JUNIUS DANIEL MDirectorAug 10Option Exercise85.002,402204,1705,298Aug 12 05:01 PM
Hunt NimrataExecutive Vice PresidentAug 10Option Exercise90.321,10699,8969,212Aug 12 05:00 PM
JUNIUS DANIEL MDirectorAug 10Sale679.582,4021,632,3552,896Aug 12 05:01 PM
SZOSTAK M ANNEDirectorAug 06Sale687.873,0002,063,6167,217Aug 09 05:02 PM
Hunt NimrataExecutive Vice PresidentAug 05Option Exercise137.9053874,1908,644Aug 09 05:00 PM
MAZELSKY JONATHAN JAYPresident & CEOAug 05Option Exercise0.00385055,606Aug 09 05:01 PM
MCKEON BRIAN PExecutive VP & CFOAug 05Option Exercise0.00192026,404Aug 09 05:01 PM
Hunt NimrataExecutive Vice PresidentAug 05Sale703.00538378,2148,106Aug 09 05:00 PM
TWIGGE GIOVANISenior Vice PresidentAug 04Option Exercise207.6810,1022,097,98728,549Aug 05 05:02 PM
TWIGGE GIOVANISenior Vice PresidentAug 04Sale700.3511,4217,998,66817,128Aug 05 05:02 PM
TWIGGE GIOVANISenior Vice PresidentAug 03Option Exercise131.0810,3501,356,70527,321Aug 05 05:02 PM
Lane MichaelExecutive Vice PresidentAug 03Option Exercise114.596,999802,03710,646Aug 05 05:01 PM
TWIGGE GIOVANISenior Vice PresidentAug 03Sale695.548,8746,172,23218,447Aug 05 05:02 PM
Lane MichaelExecutive Vice PresidentAug 03Sale691.626,9994,840,6703,647Aug 05 05:01 PM
AYERS JONATHAN WDirectorMay 28Option Exercise79.549,460752,448654,161Jun 01 06:00 PM
POLEWACZYK JAMES FExecutive Vice PresidentMay 28Option Exercise67.8510,000678,50029,915Jun 01 06:01 PM
POLEWACZYK JAMES FExecutive Vice PresidentMay 28Sale561.9110,0005,619,05719,915Jun 01 06:01 PM
Turner Kathy VSenior Vice PresidentMay 28Sale558.442,0001,116,8842,886Jun 01 06:01 PM
AYERS JONATHAN WDirectorMay 28Sale562.269,4605,318,989644,701Jun 01 06:00 PM
AYERS JONATHAN WDirectorMay 25Option Exercise79.545,000397,700658,701May 26 05:30 PM
AYERS JONATHAN WDirectorMay 25Sale552.175,0002,760,842653,701May 26 05:30 PM
AYERS JONATHAN WDirectorMay 24Option Exercise79.545,000397,700658,701May 26 05:30 PM
AYERS JONATHAN WDirectorMay 24Sale546.985,0002,734,894653,701May 26 05:30 PM
Turner Kathy VSenior Vice PresidentMay 24Sale546.242,9001,584,1004,866May 26 05:31 PM
JUNIUS DANIEL MDirectorMay 21Option Exercise85.002,500212,5005,386May 24 06:15 PM
Turner Kathy VSenior Vice PresidentMay 21Sale545.001,000545,0007,766May 24 06:15 PM
JUNIUS DANIEL MDirectorMay 21Sale539.572,5001,348,9182,886May 24 06:15 PM
AYERS JONATHAN WDirectorMay 20Option Exercise79.545,000397,700658,701May 24 06:14 PM
Turner Kathy VSenior Vice PresidentMay 20Sale537.502,0001,075,0008,766May 24 06:15 PM
AYERS JONATHAN WDirectorMay 20Sale537.065,0002,685,324653,701May 24 06:14 PM
AYERS JONATHAN WDirectorMay 18Option Exercise79.547,632607,049661,333May 20 05:33 PM
AYERS JONATHAN WDirectorMay 18Sale528.017,6324,029,809653,701May 20 05:33 PM
AYERS JONATHAN WDirectorMay 10Sale541.02512277,000653,701May 12 07:47 PM
TWIGGE GIOVANISenior Vice PresidentFeb 26Option Exercise67.853,227218,95216,950Mar 01 05:06 PM
POLEWACZYK JAMES FExecutive Vice PresidentFeb 25Option Exercise67.851,476100,14719,903Mar 01 05:05 PM
HENDERSON REBECCA MDirectorFeb 23Option Exercise160.283,046488,21317,742Feb 25 07:35 PM
AYERS JONATHAN WDirectorFeb 23Option Exercise67.851,476100,147654,213Feb 25 07:34 PM
HENDERSON REBECCA MDirectorFeb 23Sale513.413,0461,563,84014,696Feb 25 07:35 PM
JUNIUS DANIEL MDirectorFeb 22Option Exercise82.421,898156,4274,773Feb 24 05:00 PM
Underberg Sharon E.SVP, Gen. Counsel & SecretaryFeb 22Option Exercise206.9448399,9521,878Feb 24 05:01 PM
MAZELSKY JONATHAN JAYPresident & CEOFeb 22Option Exercise67.851,475100,07955,697Feb 24 05:01 PM
JUNIUS DANIEL MDirectorFeb 22Sale538.571,8981,022,2072,875Feb 24 05:00 PM
MCKEON BRIAN PExecutive VP & CFOFeb 18Option Exercise67.851,474100,01126,188Feb 19 05:01 PM
AYERS JONATHAN WDirectorFeb 18Option Exercise79.541,00079,540653,737Feb 22 06:00 PM
AYERS JONATHAN WDirectorFeb 18Sale555.561,000555,561652,737Feb 22 06:00 PM
MAZELSKY JONATHAN JAYPresident & CEOFeb 17Option Exercise52.0025,0001,300,00068,090Feb 19 05:00 PM
MAZELSKY JONATHAN JAYPresident & CEOFeb 17Sale537.2113,8687,449,96954,222Feb 19 05:00 PM
Claflin Bruce L.DirectorFeb 16Option Exercise97.057,027681,9857,331Feb 18 07:26 PM
Claflin Bruce L.DirectorFeb 16Sale536.917,3313,936,0890Feb 18 07:26 PM
Lane MichaelExecutive Vice PresidentFeb 16Sale545.00850463,2503,624Feb 17 07:31 PM
MCKEON BRIAN PExecutive VP & CFOFeb 16Sale539.581,307705,23124,714Feb 17 07:33 PM
TWIGGE GIOVANISenior Vice PresidentFeb 14Option Exercise0.001,126014,061Feb 17 07:35 PM
MCKEON BRIAN PExecutive VP & CFOFeb 14Option Exercise0.002,642027,356Feb 17 07:33 PM
POLEWACZYK JAMES FExecutive Vice PresidentFeb 14Option Exercise0.00989018,684Feb 17 07:34 PM
Turner Kathy VSenior Vice PresidentFeb 14Option Exercise0.00987011,142Feb 17 07:34 PM
MAZELSKY JONATHAN JAYPresident & CEOFeb 14Option Exercise0.003,110044,537Feb 17 07:31 PM
Hunt NimrataExecutive Vice PresidentFeb 14Option Exercise0.0071408,299Feb 17 07:30 PM
Lane MichaelExecutive Vice PresidentFeb 14Option Exercise0.0098404,768Feb 17 07:31 PM
Underberg Sharon E.SVP, Gen. Counsel & SecretaryFeb 14Option Exercise0.0070001,603Feb 17 07:35 PM
Vandebroek Sophie V.DirectorFeb 12Option Exercise160.283,046488,2136,367Feb 16 05:00 PM
Vandebroek Sophie V.DirectorFeb 12Sale538.203,0461,639,3573,321Feb 16 05:00 PM
SZOSTAK M ANNEDirectorFeb 04Option Exercise74.7811,876888,12811,876Feb 08 06:05 PM
SZOSTAK M ANNEDirectorFeb 04Sale489.7111,8765,815,8160Feb 08 06:05 PM
TWIGGE GIOVANICORPORATE VICE PRESIDENTNov 30Option Exercise67.8512,801868,54825,723Dec 02 05:01 PM
TWIGGE GIOVANICORPORATE VICE PRESIDENTNov 30Sale456.4912,8015,843,56612,922Dec 02 05:01 PM
HENDERSON REBECCA MDirectorNov 10Option Exercise85.005,902501,67020,598Nov 12 05:01 PM
HENDERSON REBECCA MDirectorNov 10Sale435.915,9022,572,74214,696Nov 12 05:01 PM
MAZELSKY JONATHAN JAYPresident & CEONov 06Option Exercise69.682,868199,84641,413Nov 09 05:01 PM
MCKEON BRIAN PExecutive VP & CFONov 06Sale476.2510,0004,762,45618,050Nov 10 07:02 PM
AYERS JONATHAN WDirectorNov 06Sale470.016,4703,040,938709,991Nov 10 07:01 PM
MAZELSKY JONATHAN JAYPresident & CEONov 05Sale469.315,2062,443,25439,145Nov 09 05:01 PM
Hunt NimrataExecutive Vice PresidentNov 05Sale470.082,098986,2287,571Nov 06 05:07 PM
AYERS JONATHAN WDirectorNov 05Sale467.1615,1347,069,988716,461Nov 06 05:06 PM
MCKEON BRIAN PExecutive VP & CFONov 04Option Exercise79.5436,2162,880,62160,916Nov 06 05:07 PM
AYERS JONATHAN WDirectorNov 04Sale471.9011,4405,398,561731,595Nov 06 05:06 PM
MCKEON BRIAN PExecutive VP & CFONov 04Sale471.4436,21617,073,80124,700Nov 06 05:07 PM
Lane MichaelExecutive Vice PresidentNov 03Option Exercise70.922,851202,1845,074Nov 05 07:51 PM
Lane MichaelExecutive Vice PresidentNov 03Sale443.001,304577,6703,770Nov 05 07:51 PM
AYERS JONATHAN WDirectorNov 03Sale443.6310,4324,627,955743,035Nov 04 05:25 PM
AYERS JONATHAN WDirectorNov 02Sale433.0110,0004,330,085753,467Nov 04 05:25 PM
ACHV Achieve Life Sciences, Inc. daily Stock Chart
ACHV [NASD]
Achieve Life Sciences, Inc.
Index- P/E- EPS (ttm)-5.08 Insider Own0.10% Shs Outstand9.45M Perf Week4.65%
Market Cap73.72M Forward P/E- EPS next Y-3.37 Insider Trans194.17% Shs Float9.38M Perf Month17.37%
Income-27.80M PEG- EPS next Q-1.10 Inst Own27.50% Short Float5.46% Perf Quarter2.27%
Sales- P/S- EPS this Y86.40% Inst Trans60.47% Short Ratio2.33 Perf Half Y-33.52%
Book/sh5.53 P/B1.47 EPS next Y27.70% ROA-75.60% Target Price- Perf Year-12.61%
Cash/sh4.62 P/C1.76 EPS next 5Y15.00% ROE-83.00% 52W Range6.63 - 16.10 Perf YTD0.12%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.48% Beta1.40
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low25.11% ATR0.48
Employees13 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)56.59 Volatility5.26% 5.73%
OptionableYes Debt/Eq0.00 EPS Q/Q8.70% Profit Margin- Rel Volume0.22 Prev Close8.11
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume219.78K Price8.30
Recom1.60 SMA204.03% SMA508.82% SMA200-13.20% Volume15,795 Change2.28%
Jun-23-21Initiated Oppenheimer Outperform $23
Sep-15-21 05:30AM  
Sep-14-21 05:30AM  
Sep-09-21 05:30AM  
Aug-16-21 05:10AM  
Aug-13-21 05:30AM  
Aug-11-21 04:05PM  
05:30AM  
Aug-03-21 05:30AM  
Jul-22-21 09:35AM  
Jul-12-21 05:57AM  
Jul-01-21 06:25AM  
Jun-29-21 05:30AM  
Jun-13-21 02:11PM  
Jun-03-21 05:30AM  
Jun-02-21 05:30AM  
May-27-21 04:05PM  
May-25-21 08:30AM  
05:55AM  
May-24-21 04:05PM  
May-15-21 03:02AM  
May-13-21 04:05PM  
02:30PM  
May-04-21 05:30AM  
Apr-22-21 05:30AM  
Apr-14-21 05:30AM  
Mar-25-21 05:30AM  
Mar-22-21 08:30AM  
Mar-16-21 05:30AM  
Mar-15-21 06:30AM  
Mar-11-21 04:05PM  
02:30PM  
Mar-04-21 05:30AM  
Mar-01-21 06:13AM  
Feb-24-21 06:30AM  
Feb-11-21 08:00AM  
Jan-26-21 07:27PM  
Jan-07-21 05:30AM  
Dec-07-20 04:05PM  
04:05PM  
Dec-03-20 08:00AM  
Nov-30-20 07:00AM  
07:00AM  
04:08AM  
Nov-24-20 11:26AM  
Nov-16-20 05:16AM  
Nov-15-20 11:16PM  
Nov-12-20 04:05PM  
04:05PM  
02:30PM  
Oct-29-20 05:30AM  
Oct-27-20 05:30AM  
Oct-08-20 06:30AM  
Oct-07-20 06:30AM  
Sep-30-20 08:00AM  
08:00AM  
Sep-21-20 06:17AM  
Sep-18-20 09:30AM  
07:00AM  
Sep-10-20 05:30AM  
Sep-03-20 05:30AM  
Aug-24-20 11:10AM  
Aug-06-20 04:05PM  
Jun-30-20 09:33AM  
Jun-29-20 08:35AM  
08:35AM  
08:30AM  
08:30AM  
Jun-05-20 02:49PM  
May-29-20 05:54AM  
May-14-20 07:30AM  
07:30AM  
May-05-20 08:00AM  
Apr-30-20 04:50PM  
Apr-06-20 05:40AM  
Apr-02-20 08:00AM  
Mar-13-20 08:00AM  
08:00AM  
Mar-12-20 05:30AM  
Mar-03-20 05:30AM  
Feb-06-20 08:00AM  
Jan-13-20 06:30AM  
Dec-23-19 05:31AM  
Dec-19-19 04:05PM  
04:05PM  
Dec-17-19 01:06PM  
01:06PM  
Dec-09-19 05:30AM  
05:30AM  
Nov-11-19 10:00AM  
Nov-06-19 06:30AM  
06:30AM  
Oct-31-19 05:30AM  
Oct-24-19 07:11AM  
05:30AM  
05:30AM  
Sep-30-19 05:30AM  
Sep-25-19 06:30AM  
Sep-13-19 05:30AM  
Sep-09-19 10:34AM  
Sep-05-19 05:30AM  
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bencich JohnCEOAug 17Option Exercise0.006806,209Aug 19 05:11 PM
JACOBS CINDYPresident & CMOAug 17Option Exercise0.00680244Aug 19 05:09 PM
Wan JerryPrincipal Accounting OfficerAug 17Option Exercise0.00110100Aug 19 05:07 PM
Bencich JohnCEOMay 27Buy7.006,00042,0006,141May 27 04:10 PM
QDEL Quidel Corporation daily Stock Chart
QDEL [NASD]
Quidel Corporation
Index- P/E7.62 EPS (ttm)20.65 Insider Own1.60% Shs Outstand41.69M Perf Week7.50%
Market Cap6.16B Forward P/E39.23 EPS next Y4.01 Insider Trans-1.26% Shs Float36.57M Perf Month32.48%
Income899.60M PEG1.06 EPS next Q0.86 Inst Own93.10% Short Float15.50% Perf Quarter41.50%
Sales1.84B P/S3.35 EPS this Y971.80% Inst Trans5.36% Short Ratio7.98 Perf Half Y14.95%
Book/sh33.85 P/B4.65 EPS next Y-45.29% ROA51.20% Target Price132.20 Perf Year-21.34%
Cash/sh15.14 P/C10.39 EPS next 5Y7.20% ROE70.80% 52W Range103.31 - 288.70 Perf YTD-12.43%
Dividend- P/FCF8.66 EPS past 5Y154.30% ROI61.30% 52W High-45.92% Beta-0.09
Dividend %- Quick Ratio3.30 Sales past 5Y53.30% Gross Margin81.30% 52W Low51.13% ATR5.70
Employees1370 Current Ratio4.40 Sales Q/Q-12.50% Oper. Margin63.30% RSI (14)67.71 Volatility4.30% 4.08%
OptionableYes Debt/Eq0.00 EPS Q/Q-71.00% Profit Margin49.00% Rel Volume0.63 Prev Close157.32
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout0.00% Avg Volume710.44K Price156.13
Recom2.50 SMA2012.06% SMA5016.18% SMA2004.22% Volume144,341 Change-0.76%
Jan-22-21Upgrade Raymond James Mkt Perform → Outperform $250
May-12-20Downgrade JP Morgan Neutral → Underweight $120 → $158
Mar-26-20Downgrade Barclays Overweight → Equal Weight $90
Oct-23-18Resumed Raymond James Strong Buy $80
Mar-08-18Upgrade Raymond James Outperform → Strong Buy
Jan-22-18Reiterated Barclays Overweight $50 → $60
Jan-04-18Upgrade CL King Neutral → Buy
Sep-19-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-17Upgrade William Blair Mkt Perform → Outperform
Jul-18-17Upgrade Canaccord Genuity Hold → Buy $25 → $42
Apr-25-17Reiterated Canaccord Genuity Hold $24 → $24.50
Feb-17-17Initiated CL King Neutral
Dec-16-16Downgrade Piper Jaffray Overweight → Neutral
Jun-13-16Upgrade Raymond James Mkt Perform → Outperform
Feb-18-16Reiterated Barclays Overweight $28 → $22
Feb-09-16Downgrade Canaccord Genuity Buy → Hold $22 → $18
Jan-08-16Reiterated Canaccord Genuity Buy $25 → $22
Dec-14-15Downgrade Raymond James Outperform → Mkt Perform
Sep-02-15Initiated Barclays Overweight $28
Jul-31-13Reiterated Canaccord Genuity Buy $30 → $35
Sep-14-21 09:58AM  
Sep-03-21 10:44AM  
Sep-02-21 06:03PM  
Sep-01-21 04:10PM  
Aug-27-21 07:00AM  
Aug-25-21 11:31AM  
Aug-18-21 01:28PM  
Aug-17-21 12:13PM  
Aug-10-21 09:00AM  
09:00AM  
Aug-06-21 03:09PM  
12:13PM  
08:11AM  
Aug-05-21 11:01PM  
08:15PM  
04:10PM  
Aug-03-21 12:30PM  
Jul-29-21 03:05PM  
Jul-28-21 07:49AM  
Jul-26-21 08:30AM  
Jul-19-21 04:29PM  
10:30AM  
Jul-14-21 04:10PM  
Jul-13-21 11:03AM  
Jul-12-21 09:15AM  
09:00AM  
Jul-08-21 05:50PM  
06:21AM  
Jul-01-21 05:50PM  
Jun-30-21 01:43AM  
Jun-29-21 06:29PM  
09:00AM  
09:00AM  
Jun-24-21 05:50PM  
01:07PM  
01:04PM  
Jun-21-21 07:30AM  
Jun-19-21 06:02AM  
Jun-18-21 05:45PM  
09:58AM  
06:35AM  
Jun-16-21 05:50PM  
Jun-14-21 08:42AM  
08:25AM  
Jun-13-21 05:18AM  
Jun-11-21 04:10PM  
08:40AM  
06:20AM  
Jun-10-21 04:45PM  
Jun-09-21 05:45PM  
Jun-07-21 11:11AM  
May-29-21 06:40AM  
May-24-21 05:10PM  
04:10PM  
May-23-21 04:08AM  
May-14-21 04:10PM  
May-07-21 01:58PM  
06:31AM  
May-06-21 08:55PM  
04:10PM  
May-05-21 08:30PM  
May-04-21 06:00PM  
12:47PM  
May-01-21 10:17AM  
Apr-30-21 09:55AM  
06:35AM  
06:20AM  
Apr-29-21 12:34PM  
09:22AM  
Apr-28-21 12:16PM  
06:19AM  
Apr-27-21 10:08AM  
09:00AM  
08:12AM  
Apr-26-21 07:00PM  
Apr-24-21 05:49AM  
Apr-23-21 08:22AM  
06:19AM  
Apr-22-21 04:32PM  
04:30PM  
Apr-21-21 05:45PM  
Apr-14-21 05:45PM  
05:04PM  
Apr-13-21 08:00AM  
08:00AM  
Apr-08-21 05:50PM  
Apr-07-21 10:15PM  
Apr-05-21 08:00AM  
08:00AM  
Apr-01-21 08:02PM  
07:30PM  
05:45PM  
02:46PM  
08:55AM  
Mar-31-21 11:30PM  
11:00PM  
Mar-30-21 06:40AM  
Mar-29-21 10:04AM  
Mar-26-21 05:45PM  
12:12PM  
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
POLAN MARY LAKE PH DDirectorSep 03Sale141.716,167873,91319,687Sep 08 07:56 PM
Kroll WernerSVP, R&DJul 01Option Exercise0.00982011,229Jul 02 06:08 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitJun 12Option Exercise0.002,00007,324Jun 16 08:23 PM
Kroll WernerSVP, R&DMay 27Option Exercise0.004,376012,495Jun 01 07:56 PM
WIDDER KENNETH JDirectorMay 16Option Exercise0.00576016,032May 18 08:00 PM
POLAN MARY LAKE PH DDirectorMay 16Option Exercise0.00485025,854May 18 07:59 PM
SLACIK CHARLES PDirectorMay 14Option Exercise0.00734012,199May 14 08:12 PM
SLACIK CHARLES PDirectorMay 13Sale113.261,000113,25811,465May 14 08:12 PM
SLACIK CHARLES PDirectorMay 12Option Exercise0.001,250012,465May 14 08:12 PM
RHOADS ANN DDirectorMay 12Option Exercise0.006240624May 14 08:10 PM
POLAN MARY LAKE PH DDirectorMay 12Option Exercise0.001,040025,369May 14 08:09 PM
ORDONEZ KATHYDirectorMay 12Option Exercise0.001,04002,896May 14 08:08 PM
Michael Edward L.DirectorMay 12Option Exercise0.001,04007,474May 14 08:06 PM
BUECHLER KENNETH FDirectorMay 12Option Exercise0.001,040060,864May 14 08:05 PM
Wilkins Joseph D Jr.DirectorMay 12Option Exercise0.002890289May 14 08:22 PM
WIDDER KENNETH JDirectorMay 12Option Exercise0.001,040015,456May 14 08:19 PM
Strobeck MatthewDirectorMay 12Option Exercise0.001,04004,909May 14 08:15 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMay 03Option Exercise23.4180318,7986,127May 04 07:45 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMay 03Sale105.7480384,9095,324May 04 07:45 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMar 17Option Exercise16.604,60176,39012,506Mar 19 07:55 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMar 17Sale136.067,4001,006,8375,106Mar 19 07:55 PM
Kroll WernerSVP, R&DFeb 24Sale173.715,283917,7348,119Feb 24 07:53 PM
Kroll WernerSVP, R&DFeb 23Sale166.304,835804,05813,402Feb 24 07:53 PM
Kroll WernerSVP, R&DFeb 22Option Exercise43.5412,784556,67431,021Feb 24 07:53 PM
BRYANT DOUGLAS CPresident & CEOFeb 22Buy165.305,000826,500495,807Feb 22 07:40 PM
Kroll WernerSVP, R&DFeb 22Sale164.1112,7842,097,95518,237Feb 24 07:53 PM
POLAN MARY LAKE PH DDirectorDec 01Sale192.2511,0002,114,79724,329Dec 03 07:32 PM
POLAN MARY LAKE PH DDirectorNov 06Sale284.173,000852,50535,329Nov 06 07:19 PM
SLACIK CHARLES PDirectorNov 05Option Exercise20.824,00983,46715,224Nov 06 07:16 PM
SLACIK CHARLES PDirectorNov 05Sale282.464,0091,132,38811,215Nov 06 07:16 PM
POLAN MARY LAKE PH DDirectorOct 23Option Exercise21.6327,188588,14238,329Oct 27 07:37 PM
POLAN MARY LAKE PH DDirectorOct 12Sale275.8311,7433,239,01511,141Oct 14 07:26 PM
ABIO ARCA biopharma, Inc. daily Stock Chart
ABIO [NASD]
ARCA biopharma, Inc.
Index- P/E- EPS (ttm)-1.54 Insider Own0.40% Shs Outstand14.41M Perf Week2.55%
Market Cap42.85M Forward P/E- EPS next Y- Insider Trans54.41% Shs Float14.35M Perf Month5.59%
Income-16.10M PEG- EPS next Q- Inst Own8.40% Short Float2.81% Perf Quarter-10.91%
Sales- P/S- EPS this Y50.20% Inst Trans38.77% Short Ratio1.40 Perf Half Y-22.96%
Book/sh4.25 P/B0.71 EPS next Y- ROA-27.10% Target Price- Perf Year-34.77%
Cash/sh4.45 P/C0.68 EPS next 5Y- ROE-28.60% 52W Range2.72 - 5.50 Perf YTD-24.69%
Dividend- P/FCF- EPS past 5Y42.50% ROI- 52W High-45.09% Beta2.69
Dividend %- Quick Ratio17.50 Sales past 5Y- Gross Margin- 52W Low11.03% ATR0.11
Employees11 Current Ratio17.50 Sales Q/Q- Oper. Margin- RSI (14)48.44 Volatility3.58% 3.64%
OptionableYes Debt/Eq0.00 EPS Q/Q53.80% Profit Margin- Rel Volume0.31 Prev Close3.02
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume288.12K Price3.02
Recom- SMA20-1.09% SMA50-0.34% SMA200-18.57% Volume28,170 Change0.00%
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Sep-16-21 08:30AM  
Aug-16-21 08:05AM  
Aug-12-21 01:15AM  
Aug-09-21 08:00AM  
Aug-04-21 04:15PM  
Jul-28-21 08:00AM  
Jul-13-21 08:00AM  
Jul-09-21 08:00AM  
Jul-08-21 11:20AM  
Jul-07-21 08:00AM  
Jun-23-21 09:35AM  
May-11-21 04:15PM  
May-05-21 04:05PM  
May-03-21 04:30PM  
Mar-18-21 04:30PM  
Feb-13-21 01:09AM  
Dec-15-20 08:30AM  
Dec-09-20 05:40PM  
Nov-23-20 12:28PM  
08:30AM  
Nov-02-20 08:30AM  
Oct-07-20 08:30AM  
Oct-05-20 04:30PM  
Sep-21-20 08:00AM  
Aug-17-20 08:49AM  
Aug-12-20 08:00AM  
Aug-05-20 04:15PM  
Jul-07-20 08:30AM  
Jun-03-20 09:56AM  
09:56AM  
Jun-01-20 08:20AM  
May-29-20 12:24PM  
09:59AM  
May-28-20 04:19PM  
12:14PM  
10:27AM  
08:00AM  
May-07-20 08:30AM  
May-06-20 04:30PM  
Feb-18-20 04:30PM  
Feb-01-20 08:31AM  
Nov-06-19 04:10PM  
Nov-03-19 08:47AM  
Sep-12-19 08:30AM  
Sep-11-19 08:30AM  
Sep-04-19 01:37PM  
Aug-21-19 09:49AM  
Aug-01-19 04:30PM  
Jun-04-19 07:09AM  
May-13-19 09:00AM  
May-08-19 04:30PM  
May-01-19 08:30AM  
Apr-23-19 08:30AM  
Mar-18-19 08:30AM  
Mar-06-19 08:00AM  
Feb-27-19 04:15PM  
Feb-20-19 07:30AM  
Jan-16-19 08:30AM  
Dec-26-18 11:47AM  
Dec-20-18 04:01PM  
Nov-14-18 04:30PM  
Nov-12-18 08:30AM  
Nov-05-18 08:30AM  
Oct-10-18 04:16PM  
Oct-02-18 08:00AM  
Sep-18-18 08:30AM  
Aug-09-18 04:15PM  
Aug-03-18 09:45AM  
Jul-31-18 12:15PM  
08:30AM  
08:10AM  
Jun-19-18 07:05AM  
May-29-18 08:30AM  
May-11-18 08:20AM  
May-10-18 08:30AM  
07:15AM  
May-08-18 04:15PM  
Apr-23-18 08:30AM  
Apr-03-18 07:20AM  
Mar-22-18 04:30PM  
Feb-27-18 03:00PM  
Feb-26-18 02:18PM  
08:00AM  
Jan-23-18 05:13PM  
Jan-08-18 08:30AM  
Jan-02-18 05:09PM  
Dec-08-17 06:13PM  
Nov-30-17 02:25PM  
Nov-20-17 08:05AM  
Nov-17-17 08:10AM  
Nov-16-17 08:30AM  
Nov-09-17 04:05PM  
Oct-23-17 08:16PM  
Sep-21-17 08:30AM  
Aug-16-17 08:30AM  
Aug-09-17 04:30PM  
Aug-03-17 04:15PM  
Jun-20-17 08:30AM  
May-15-17 08:30AM  
Apr-26-17 08:30AM  
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CONWAY ROBERT EChairman of the BoardMay 12Buy3.1910,00031,94750,000May 13 05:00 PM
CONWAY ROBERT EChairman of the BoardMay 05Buy3.2310,00032,34540,000May 06 04:30 PM
CONWAY ROBERT EChairman of the BoardDec 18Buy4.1610,00041,63030,000Dec 21 04:15 PM
CONWAY ROBERT EChairman of the BoardSep 25Buy4.285,00021,39920,000